G-Force PD: a global initiative in coordinating stem cell-based dopamine treatments for Parkinson’s disease

npj Parkinson's Disease

Volumn 1, Issue 1, 2015, Pages

  Barker, Roger A ^a   Studer, Lorenz ^b   Cattaneo, Elena ^c   Takahashi, Jun ^d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84963754200     PISSN: None     EISSN: 23738057     Source Type: Journal    
DOI: 10.1038/npjparkd.2015.17     Document Type: Review

References (14)

1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014; 311: 1670–1683.
2. Jenner P. Treatment of the later stages of Parkinson's disease—pharmacological approaches now and in the future. Transl Neurodegener 2015; 4: 3.
3. Brundin P, Barker RA, Parmar M. Neural grafting in Parkinson's disease Problems and possibilities. Prog Brain Res 2010; 184: 265–294.
4. Barker RA, Barrett J, Mason SL, Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol 2013; 12: 84–91.
5. Kefalopoulou Z, Politis M, Piccini P, Mencacci N, Bhatia K, Jahanshahi M et al. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. JAMA Neurol 2014; 71: 83–87.
6. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001; 344: 710–719.
7. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403–414.
8. Abbott A. Fetal-cell revival for Parkinson's. Nature 2014; 510: 195–196.
9. Barker RA. Developing stem cell therapies for Parkinson's disease: waiting until the time is right. Cell Stem Cell 2014; 15: 539–542.
10. Steinbeck JA, Studer L. Moving stem cells to the clinic: potential and limitations for brain repair. Neuron 2015; 86: 187–206.
11. Kriks S, Shim JW, Piao J, Ganat YM, Wakeman DR, Xie Z et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 2011; 480: 547–551.
12. Grealish S, Diguet E, Kirkeby A, Mattsson B, Heuer A, Bramoulle Y et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell Stem Cell 2014; 15: 653–665.
13. de Melo-Martin I, Hellmers N, Henchcliffe C. First-in-human cell transplant trials in Parkinson's disease: the need for an improved informed consent process. Parkinsonism Relat Disord 2015; 21: 829–832.
14. Doi D, Samata B, Katsukawa M, Kikuchi T, Morizane A, Ono Y et al. Isolation of human induced pluripotent stem cell-derived dopaminergic progenitors by cell sorting for successful transplantation. Stem Cell Rep 2014; 2: 337–350.